Ide-Cel versus Cilta-Cel for Refractory MM: What Is the Bottom Line for Patients?

25 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Blood Cancers Today caught up with Krina Patel, MD, MSc, co-editor-in-chief for the BCT Editorial Board, about her recent clinical research work in multiple myeloma. Dr. Patel is based at the University of Texas MD Anderson Cancer Center in Houston, where she is the section chief and research lead for multiple myeloma, as well as an associate professor in the Department of Lymphoma and Myeloma.

Dr. Patel was a member of a study team that compared standard-of-care idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for relapsed or refractory multiple myeloma. Doris Hansen, MD, of the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, led the study, and its findings were published in Journal of Clinical Oncology.1

In this interview segment, Dr. Patel explained that this study addressed a lack of prospective studies that directly compare these two interventions for multiple myeloma. She highlighted that the execution of the study stressed minimization of bias in handling retrospective data. Dr. Patel also gave a practical takeaway for clinicians’ decision-making from this comparison of ide-cel and cilta-cel that the latter features greater efficacy but increased toxicity.

Reference:
1. Hansen DK, et al. J Clin Oncol. 2025;43(13):1597-1609. doi:10.1200/JCO-24-01730

------------
Blood Cancers Today is a new publication that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, bloodcancerstoday.com is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings.

Blood Cancers Today was developed to reach all professionals in the hematology/oncology universe, covering the latest news and analysis in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, and other hematologic malignancies.
Categoria
Oncology
Commenta per primo questo video.

Prossimo